Human monoclonal antibodies that inhibit binding of hepatitis C virus E2 protein to CD81 and recognize conserved conformational epitopes
about
DC-SIGN and L-SIGN are high affinity binding receptors for hepatitis C virus glycoprotein E2Monoclonal antibodies: Principles and applications of immmunodiagnosis and immunotherapy for hepatitis C virusGenetic Diversity Underlying the Envelope Glycoproteins of Hepatitis C Virus: Structural and Functional Consequences and the Implications for Vaccine DesignHepatitis C virus molecular evolution: transmission, disease progression and antiviral therapyNeutralizing antibody response to hepatitis C virusSpatiotemporal analysis of hepatitis C virus infectionMolecular determinants and dynamics of hepatitis C virus secretionMapping B-cell epitopes of hepatitis C virus E2 glycoprotein using human monoclonal antibodies from phage display librariesMonoclonal Antibody AP33 Defines a Broadly Neutralizing Epitope on the Hepatitis C Virus E2 Envelope GlycoproteinAnalysis of a Highly Flexible Conformational Immunogenic Domain A in Hepatitis C Virus E2Hepatitis C virus induces toll-like receptor 4 expression, leading to enhanced production of beta interferon and interleukin-6Analysis of antigenicity and topology of E2 glycoprotein present on recombinant hepatitis C virus-like particles.Preclinical Evaluation of Two Neutralizing Human Monoclonal Antibodies against Hepatitis C Virus (HCV): a Potential Treatment To Prevent HCV Reinfection in Liver Transplant PatientsSubcellular localization of hepatitis C virus structural proteins in a cell culture system that efficiently replicates the virusRecognition of native hepatitis C virus E1E2 heterodimers by a human monoclonal antibody.Different Domains of CD81 Mediate Distinct Stages of Hepatitis C Virus Pseudoparticle EntryEvaluating Replication-Defective Vesicular Stomatitis Virus as a Vaccine VehicleComplement-mediated enhancement of antibody function for neutralization of pseudotype virus containing hepatitis C virus E2 chimeric glycoproteinCharacterization of an Immunodominant Antigenic Site on GB Virus C Glycoprotein E2 That Is Involved in Cell BindingImmunogenic and Functional Organization of Hepatitis C Virus (HCV) Glycoprotein E2 on Infectious HCV VirionsA focus reduction neutralization assay for hepatitis C virus neutralizing antibodiesThe Neutralizing Activity of Anti-Hepatitis C Virus Antibodies Is Modulated by Specific Glycans on the E2 Envelope ProteinExpression and Characterization of a Minimal Hepatitis C Virus Glycoprotein E2 Core Domain That Retains CD81 BindingIdentification of a Broadly Cross-Reacting and Neutralizing Human Monoclonal Antibody Directed against the Hepatitis C Virus E2 ProteinAntibody-Dependent Enhancement of Hepatitis C Virus InfectionStructural elucidation of critical residues involved in binding of human monoclonal antibodies to hepatitis C virus E2 envelope glycoproteinCD81-Dependent Binding of Hepatitis C Virus E1E2 HeterodimersA Point Mutation Leading to Hepatitis C Virus Escape from Neutralization by a Monoclonal Antibody to a Conserved Conformational EpitopeDefinition of a Conserved Immunodominant Domain on Hepatitis C Virus E2 Glycoprotein by Neutralizing Human Monoclonal AntibodiesHepatitis C Virus (HCV)-Induced Immunoglobulin Hypermutation Reduces the Affinity and Neutralizing Activities of Antibodies against HCV Envelope ProteinIn vitro selection of a neutralization-resistant hepatitis C virus escape mutantMutations in Hepatitis C Virus E2 Located outside the CD81 Binding Sites Lead to Escape from Broadly Neutralizing Antibodies but Compromise Virus InfectivityProduction of Infectious Genotype 1b Virus Particles in Cell Culture and Impairment by Replication Enhancing MutationsLow pH-dependent Hepatitis C Virus Membrane Fusion Depends on E2 Integrity, Target Lipid Composition, and Density of Virus ParticlesHepatitis C Virus (HCV) Infection May Elicit Neutralizing Antibodies Targeting Epitopes Conserved in All Viral GenotypesIdentification and Characterization of Broadly Neutralizing Human Monoclonal Antibodies Directed against the E2 Envelope Glycoprotein of Hepatitis C VirusRNA Interference and Single Particle Tracking Analysis of Hepatitis C Virus EndocytosisThe Disulfide Bonds in Glycoprotein E2 of Hepatitis C Virus Reveal the Tertiary Organization of the MoleculePersistent hepatitis C virus infection in microscale primary human hepatocyte culturesToward a Hepatitis C Virus Vaccine: the Structural Basis of Hepatitis C Virus Neutralization by AP33, a Broadly Neutralizing Antibody
P2860
Q24296260-66565BD6-324D-4B7B-9499-DB3E203EC279Q26783378-FB6D4FD6-CC3D-4760-A640-616561702AC5Q26801759-55405EDD-34C9-4EBA-81B4-03C8462A47B6Q26853500-0EDC50BE-AC95-48CA-84E0-63A9516A5E21Q27027484-2FF9CC85-C2C3-4244-B9E3-29C490528ED9Q27320822-1E5AAED1-6A09-4A7E-A946-170ABFF1C8CFQ27347838-EA1D326D-3B89-43DB-AB64-F2A25A1DFD89Q27469875-709F0CC3-64B8-43A7-B9B4-6218F772F772Q27470798-7DF2BA07-289C-44A8-B289-52E9357AF1EBQ27472672-109DADF8-A2AF-40FB-8E4F-44C292ED25C7Q27472816-575DBAB9-6127-4707-8282-54E30F8CB0D6Q27472891-7A823EE2-F4D7-4A26-92C3-10ACDDD61068Q27473046-369B1B8A-2099-44C7-A1D9-275EE29C69A0Q27473047-2085F632-65D6-4B03-B0B3-94FC36459BA9Q27473084-3F2176D6-8B81-48BC-91E3-75A605A6D943Q27473222-A34F4A55-1787-4EC1-A792-B53BAA27BDE3Q27473287-F68223E7-237D-4963-9330-DE36126460A4Q27473461-43696705-E133-4D62-964E-7A8D0928260BQ27477720-0337B9B3-1641-4C63-BF50-F17ADE390E03Q27478035-9DE04307-DFAE-4FE8-A9C5-F9C5C6ED5104Q27478295-C91E336B-AAC9-41A9-B4AE-4172A8BE0992Q27481009-3151FE91-ADC7-4BA6-BCD1-5F772B728E82Q27481026-FA98262D-5CE1-4EFC-8D70-B6B360ABDB0EQ27485318-78398B51-05F1-4DA4-84E4-B813F94E797DQ27485451-1C719769-7881-4963-B736-6F1103DA2EB2Q27485636-12AB407C-FD0A-48EC-8A74-3F4309950C29Q27485659-10089987-E7A4-4187-9F7F-767A5B5DFBA8Q27486113-C6F0D20F-EDA8-4EB9-9F6B-BB3B4EA7812CQ27486115-AE1A9A0E-A00C-4C30-AC26-B078B2714A15Q27486411-A246E294-FE88-4DE0-87B2-C73A7703328EQ27487549-7C8A3A84-8AB0-4F44-8380-FB3C7D2512E9Q27488430-173EB7AE-3382-4B03-A984-6D5CC3B7B115Q27488616-C3CBC5AB-726B-457D-A22E-6DEB25C78E77Q27489056-6AF4DA0A-F5FE-4AAD-B742-F74190D1B056Q27490450-F3330C84-25C6-4816-BB67-668899DE9C5DQ27490467-0A78E51A-B850-41D4-AB4E-17ADEE6889AEQ27490501-0DA397EF-EE70-4685-BF35-68A71C10C2F9Q27490948-F1697538-487D-4080-8371-F8358FA0359DQ27491284-B04C8851-26F9-46AB-88E3-79E9E9AA36B8Q27673453-A5CD34FE-3A84-4187-98C5-9A9463753E07
P2860
Human monoclonal antibodies that inhibit binding of hepatitis C virus E2 protein to CD81 and recognize conserved conformational epitopes
description
2000 nî lūn-bûn
@nan
2000 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
Human monoclonal antibodies th ...... served conformational epitopes
@ast
Human monoclonal antibodies th ...... served conformational epitopes
@en
Human monoclonal antibodies th ...... served conformational epitopes
@nl
type
label
Human monoclonal antibodies th ...... served conformational epitopes
@ast
Human monoclonal antibodies th ...... served conformational epitopes
@en
Human monoclonal antibodies th ...... served conformational epitopes
@nl
prefLabel
Human monoclonal antibodies th ...... served conformational epitopes
@ast
Human monoclonal antibodies th ...... served conformational epitopes
@en
Human monoclonal antibodies th ...... served conformational epitopes
@nl
P2093
P2860
P1433
P1476
Human monoclonal antibodies th ...... served conformational epitopes
@en
P2093
K G Hadlock
R E Lanford
P2860
P304
10407-10416
P356
10.1128/JVI.74.22.10407-10416.2000
P577
2000-11-01T00:00:00Z